Fauser B C
Department of Obstetrics and Gynaecology, Dijkzigt Academic Hospital, Rotterdam, The Netherlands.
Mol Hum Reprod. 1996 May;2(5):327-34. doi: 10.1093/molehr/2.5.327.
This review summarizes observations on the background and potential clinical significance of interference with follicle stimulating hormone (FSH) regulation of human ovarian function. This interference may occur at the level of the pituitary by the secretion of FSH isoforms with reduced or absent bioactivity. In addition, interference with FSH may occur in the circulation, or within the ovarian follicular compartment. Although the full range of its significance remains to be elucidated, there are distinct indications that these mechanisms may be involved in normal ovarian physiology, as well as in abnormal response of the ovary to stimulation by endogenous FSH or by exogenously-administered gonadotrophin preparations. Moreover, recent advances in the determination of the structure-function relationship of FSH and FSH-receptor interaction, in combination with new developments in recombinant DNA technology, will allow the production of modified FSH- or FSH receptor-like molecules with altered bioactivity. The availability of FSH agonists and antagonists in the near future should provide a challenge for clinicians to improve treatment outcome and to find new indications for the use of these compounds.
本综述总结了关于干扰促卵泡激素（FSH）对人类卵巢功能调节的背景及潜在临床意义的观察结果。这种干扰可能通过分泌生物活性降低或缺失的FSH异构体在垂体水平发生。此外，对FSH的干扰可能发生在循环系统中，或卵巢滤泡腔内。尽管其全部意义仍有待阐明，但有明确迹象表明，这些机制可能参与正常卵巢生理过程，以及卵巢对内源性FSH或外源性促性腺激素制剂刺激的异常反应。此外，FSH与FSH受体相互作用的结构-功能关系测定方面的最新进展，结合重组DNA技术的新发展，将能够生产出生物活性改变的修饰FSH或FSH受体样分子。在不久的将来，FSH激动剂和拮抗剂的可得性将给临床医生带来挑战，促使他们改善治疗效果并找到这些化合物的新用途。
